<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BackgroundThe <z:chebi fb="0" ids="22333">alkylating agent</z:chebi> temozolomide (TMZ) is widely used for the treatment of <z:hpo ids='HP_0009733'>gliomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Although reports of treatment-related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), and <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) associated with TMZ are accumulating, it remains unclear whether TMZ has the same leukemogenic potential as other <z:chebi fb="0" ids="22333">alkylating agents</z:chebi>.MethodsWe performed a single-institution retrospective analysis using a database of 359 <z:hpo ids='HP_0009733'>glioma</z:hpo> patients given nimustine (<z:chebi fb="0" ids="7576">ACNU</z:chebi>)-based therapy, TMZ-based therapy, or combination therapy, who were followed up for a minimum of 2 months, between January 1990 and December 2009, at the National <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Center Hospital in Japan.ResultsOf the 359 patients, 225 received <z:chebi fb="0" ids="7576">ACNU</z:chebi> alone or <z:chebi fb="0" ids="7576">ACNU</z:chebi> plus other chemotherapeutic drugs (<z:chebi fb="0" ids="7576">ACNU</z:chebi>-based group; median follow-up period, 31.4 mo), 63 patients received <z:chebi fb="0" ids="7576">ACNU</z:chebi>-based therapy followed by TMZ therapy (<z:chebi fb="0" ids="7576">ACNU</z:chebi>-TMZ group; median follow-up period, 19.1 mo), and 71 patients received TMZ alone or TMZ plus other chemotherapeutic drugs (TMZ-based group; median follow-up period, 16.9 mo) </plain></SENT>
<SENT sid="2" pm="."><plain>Three patients in the <z:chebi fb="0" ids="7576">ACNU</z:chebi>-based group developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (incidence rate: 2.9 cases per 1000 person-years), 2 patients in the <z:chebi fb="0" ids="7576">ACNU</z:chebi>-TMZ group developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (13.0 cases per 1000 person-years), and 1 patient in the TMZ-based group developed ALL (9.9 cases per 1000 person-years).ConclusionsDespite the limitations of this study, published reports and our results suggest that TMZ induces secondary <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e>, particularly ALL, and might shorten the latency period when used in combination with other chemotherapeutic agents </plain></SENT>
</text></document>